A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes
Eli Lilly and Company
View at source ↗Clinical trial
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Brief summary
The purpose of this study is to investigate the efficacy and safety of eloralintide and tirzepatide coformulation (EloraTZP) compared with tirzepatide, eloralintide and placebo for body weight reduction in participants with obesity. Participation in the study will last about 2 years.
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Trial details
- acronym
- AMPLIFY-1
- status
- NOT_YET_RECRUITING
- phase
- PHASE3
- study type
- INTERVENTIONAL
- enrollment
- 2115
- sponsor
- Eli Lilly and Company
- conditions
- Obesity
- interventions
- DRUG: eloralintide and tirzepatide; DRUG: Eloralintide; DRUG: Tirzepatide; DRUG: Placebo
- start date
- 2026-12-01
- start date type
- ESTIMATED
- primary completion date
- 2029-10-01
- has results
- false
- data source
- ClinicalTrials.gov
- data processed
- 2026-10-29T09:00:05
- modifications
- selected fields only; whitespace normalized; brief summary truncated to 2,000 characters
Record
- Archive ID
- nct:NCT07881432
- Published
- Oct 19, 2026
- Venue
- ClinicalTrials.gov
- ClinicalTrials.gov
- NCT07881432
- Categories
- Obesity
- License
- ClinicalTrials.gov terms (attribution, processing date, modifications noted)
- Provenance
- clinicaltrials